Roubos N, Rosenfeldt F L, Richards S M, Conyers R A, Davis B B
Baker Medical Research Institute, Melbourne, Australia.
Circulation. 1995 Nov 1;92(9 Suppl):II31-6. doi: 10.1161/01.cir.92.9.31.
High-pressure distension during harvesting damages the saphenous vein (SV) and may contribute to subsequent coronary artery bypass graft (CABG) occlusion. Application of vasodilator agents to the SV during harvesting may reduce the need for high-pressure distension and improve graft quality. We tested the effects of a vasodilator solution containing glyceryl trinitrate and verapamil (GV) or the conventional agent papaverine (Pap) on the pressure necessary to overcome SV spasm and on the structure and biochemistry of the SV graft.
Thirty-six patients undergoing CABG were randomly allocated to receive an application of either topical and intraluminal GV solution, topical Pap, or topical and intraluminal Ringer's solution (untreated) to the SV during harvesting. The peak and mean pressures required to distend the vein were recorded. Samples of SV were taken for microscopy and biochemical analysis just before we performed the anastomosis. The percentage of endothelial coverage was calculated by area measurements of stained en face preparations of the vein intima. The results for peak pressures (mmHg) were: untreated, 479.2 +/- 27.5; Pap, 384.8 +/- 29.0; and GV, 309.5 +/- 28.3 (P < .001, GV plus Pap versus untreated); and the results for mean pressures (mm Hg) were untreated, 136.2 +/- 9.6; Pap, 102.2 +/- 10.8; and GV, 98.0 +/- 8.3 (P < .01, GV plus Pap versus untreated). The results for endothelial cover (%) were: untreated, 43.7 +/- 7.0; Pap, 44.1 +/- 9.2; and GV, 68.7 +/- 7.0 (P < .05, GV versus Pap); and the results for ATP (nmol/g wet wt) were: untreated, 67.3 +/- 12.7; Pap, 112.0 +/- 19.4; and GV, 132.5 +/- 22.7 (P < .05, GV plus Pap versus untreated).
First, pharmacological treatment of SV during harvesting, especially with GV solution, allows the use of a lower distension pressure and reduces the breakdown of high-energy phosphates in the vein wall. Second, topical and intraluminal use of GV solution during vein harvesting improves endothelial coverage compared with the topical use of Pap or no pharmacological treatment.
采集过程中的高压扩张会损伤大隐静脉(SV),并可能导致后续冠状动脉旁路移植术(CABG)堵塞。在采集过程中对大隐静脉应用血管扩张剂可能会减少对高压扩张的需求并提高移植物质量。我们测试了含有硝酸甘油和维拉帕米的血管扩张剂溶液(GV)或传统药物罂粟碱(Pap)对克服大隐静脉痉挛所需压力以及大隐静脉移植物的结构和生物化学的影响。
36例接受冠状动脉旁路移植术的患者在采集大隐静脉时被随机分配接受局部和腔内应用GV溶液、局部应用罂粟碱或局部和腔内应用林格氏液(未治疗)。记录扩张静脉所需的峰值压力和平均压力。在进行吻合之前采集大隐静脉样本用于显微镜检查和生化分析。通过对静脉内膜染色的正面制剂进行面积测量来计算内皮覆盖百分比。峰值压力(mmHg)的结果为:未治疗组,479.2±27.5;罂粟碱组,384.8±29.0;GV组,309.5±28.3(P<.001,GV加罂粟碱组与未治疗组相比);平均压力(mmHg)的结果为:未治疗组,136.2±9.6;罂粟碱组,102.2±10.8;GV组,98.0±8.3(P<.01,GV加罂粟碱组与未治疗组相比)。内皮覆盖(%)的结果为:未治疗组,43.7±7.0;罂粟碱组,44.1±9.2;GV组,68.7±7.0(P<.05,GV组与罂粟碱组相比);三磷酸腺苷(ATP,nmol/g湿重)的结果为:未治疗组,67.3±12.7;罂粟碱组,112.0±19.4;GV组,132.5±22.7(P<.05,GV加罂粟碱组与未治疗组相比)。
第一,在采集大隐静脉期间进行药物治疗,尤其是使用GV溶液,可允许使用较低的扩张压力并减少静脉壁中高能磷酸盐的分解。第二,与局部应用罂粟碱或不进行药物治疗相比,在静脉采集期间局部和腔内使用GV溶液可改善内皮覆盖。